Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Haemonetics Corp (HAE)

Haemonetics Corp (HAE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,037,358
  • Shares Outstanding, K 50,683
  • Annual Sales, $ 967,580 K
  • Annual Income, $ 55,020 K
  • 60-Month Beta 0.77
  • Price/Sales 6.31
  • Price/Cash Flow 26.02
  • Price/Book 10.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.77
  • Number of Estimates 5
  • High Estimate 0.82
  • Low Estimate 0.74
  • Prior Year 0.63
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
117.62 +2.74%
on 11/11/19
130.75 -7.58%
on 11/01/19
-6.41 (-5.04%)
since 10/18/19
3-Month
115.93 +4.24%
on 09/10/19
137.71 -12.25%
on 08/20/19
-15.75 (-11.53%)
since 08/19/19
52-Week
80.24 +50.61%
on 04/18/19
140.36 -13.91%
on 08/19/19
+17.99 (+17.49%)
since 11/19/18

Most Recent Stories

More News
Zimmer (ZBH) Hits 52-Week High: What's Driving the Stock?

Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent positive developments.

ZBH : 144.54 (-0.31%)
HAE : 120.84 (+1.44%)
NUVA : 72.52 (-0.10%)
RMD : 149.39 (+1.09%)
Edwards Lifesciences (EW) Recalls PASCAL's Guide Sheath

Edwards Lifesciences (EW) issues a product recall for its guide sheath based on report from its urgent field safety notice.

NUVA : 72.52 (-0.10%)
HAE : 120.84 (+1.44%)
EW : 243.56 (+0.49%)
RMD : 149.39 (+1.09%)
InMode (INMD) Looks Good: Stock Adds 5.6% in Session

InMode (INMD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

HAE : 120.84 (+1.44%)
INMD : 55.84 (+6.91%)
QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes

QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.

HAE : 120.84 (+1.44%)
RMD : 149.39 (+1.09%)
NUVA : 72.52 (-0.10%)
QGEN : 41.04 (-0.02%)
Amedisys Partners With nVoq to Improve Clinician Experience

Amedisys (AMED) aims to enhance clinician workflow by integrating nVoq's technology platform into its home health business.

HAE : 120.84 (+1.44%)
RMD : 149.39 (+1.09%)
NUVA : 72.52 (-0.10%)
AMED : 154.15 (-0.50%)
Haemonetics (HAE) Grows on New Products, Robust Plasma Sales

Haemonetics (HAE) witnesses a steady uptick in Plasma franchise, fueled by favorable price, volume and mix.

EW : 243.56 (+0.49%)
NUVA : 72.52 (-0.10%)
GWPH : 103.56 (+1.06%)
HAE : 120.84 (+1.44%)
Insulet (PODD) Hits a 52-Week High: What's Driving the Stock?

Insulet (PODD) has been gaining from several positive developments recently.

HAE : 120.84 (+1.44%)
PODD : 180.89 (-0.88%)
RMD : 149.39 (+1.09%)
NUVA : 72.52 (-0.10%)
Here's Why You Should Hold on to CVS Health (CVS) For Now

Investors can still hold on to CVS Health (CVS) stock, thanks to its solid prospects.

NUVA : 72.52 (-0.10%)
HAE : 120.84 (+1.44%)
GWPH : 103.56 (+1.06%)
CVS : 75.35 (+0.33%)
CVS Health's New Plans With Aetna May Improve Health Outcomes

CVS Health's (CVS) Health Care Benefits segment develops Medicare program with Aetna.

NUVA : 72.52 (-0.10%)
HAE : 120.84 (+1.44%)
GWPH : 103.56 (+1.06%)
CVS : 75.35 (+0.33%)
Syneos Health Collaborates with AiCure for Patient Engagement

Syneos Health (SYNH) aims to optimize patient engagement and trial success by partnering with AiCure.

HAE : 120.84 (+1.44%)
NUVA : 72.52 (-0.10%)
GWPH : 103.56 (+1.06%)
SYNH : 51.66 (+1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade HAE with:

Business Summary

Haemonetics Corporation is a Global Leader in Blood Management Solutions. Their comprehensive portfolio of devices, information management, consulting services offers blood management solutions for each facet of the blood supply chain from plasma blood collectors to hospitals. They believe that through...

See More

Key Turning Points

2nd Resistance Point 122.52
1st Resistance Point 121.68
Last Price 120.84
1st Support Level 119.77
2nd Support Level 118.70

See More

52-Week High 140.36
Last Price 120.84
Fibonacci 61.8% 117.39
Fibonacci 50% 110.30
Fibonacci 38.2% 103.20
52-Week Low 80.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar